Did You Know...
...that the x-ray was discovered purely by accident? When German physicist Wilhelm Konrad von Roentgen was experimenting with cathode rays in 1895, he put an activated Crookes tube in a book and went out to lunch. When he returned, he discovered that a key that had also been placed in the book showed up as an image on the developed film!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20080305081 | Novel aminopyrimidine derivatives as PLK1 inhibitors The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are... | 12/11/2008 |
| 20080299074 | A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on am... | 12/04/2008 |
| 20080292585 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmace... | 11/27/2008 |
| 20080292712 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF BIOACTIVE MOLECULES Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synth... | 11/27/2008 |
| 20080279812 | Disease Prevention and Vaccination Prior to Thymic Reactivation The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient by disrupting sex steroid signalling in the patient, wherein the bone marrow and other immune ce... | 11/13/2008 |
| 20080279813 | Cd4+ Cd25+ T-Cells Activated to a Specific Antigen The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating a... | 11/13/2008 |
| 20080274081 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytoki... | 11/06/2008 |
| 20080267915 | Hcv Ns3-Ns4a Protease Inhibition The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the i... | 10/30/2008 |
| 20080260689 | PEPTIDES FOR ACTIVE ANTI-CYTOKINE IMMUNIZATION Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cyt... | 10/23/2008 |
| 20080260820 | Oral dosage formulations of protease-resistant polypeptides Oral dosage formulations of the protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsu... | 10/23/2008 |
| 20080253993 | Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope Disclosed is a method for inducing an immune response against autologous Epidermal Growth Factor Receptor (EGFR) in humans. The method comprises effecting uptake by antigen presenting cells of epitopes (preferably all) from the extracellular portion of human EGFR and of... | 10/16/2008 |
| 20080241100 | PHARMACEUTICAL COMPOSITION COMPRISING A CYTOKINE The present invention relates to a pharmaceutical composition comprising, (i) a cytokine and, (ii) a compound of the general formula (Ih) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer there... | 10/02/2008 |
| 20080233083 | Methods and Compositions for Vaccination of Animals with Prrsv Antigens with Improved Immunogenicity Pigs challenged with hypoglycosylated variants of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) major surface protein GP5 exhibited increased production of PRRSV-neutralizing antibodies relative to the levels of neurtalizing antibodies produced by pigs imm... | 09/25/2008 |
| 20080226596 | Therapeutic compositions and methods useful in treating hepatitis The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment conta... | 09/18/2008 |
| 20080219950 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to no... | 09/11/2008 |
| 20080219951 | Stabilization of Biologically Active Proteins With Mixtures of Polysaccharides and Amino Acid Based Compounds The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable... | 09/11/2008 |
| 20080213216 | Methods of stimulating phagocytosis The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess... | 09/04/2008 |
| 20080193412 | Method of Enhancing the Immune Response to a Vaccine A method for enhancing the immune response to an antigen or vaccine comprising administering an effective amount of a Th1 stimulatory cytokine, preferably interferon, oromucosally at substantially the same time as administration of an effective amount of an antigen or v... | 08/14/2008 |
| 20080193413 | Anti-Infective Agents Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthet... | 08/14/2008 |
| 20080193410 | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH... | 08/14/2008 |
| 20080187515 | Use of Immunoconjugates to Enhance the Efficacy of Multi-Stage Cascade Boosting Vaccines Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tumor ... | 08/07/2008 |
| 20080171016 | Death Domain Containing Receptors The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins.... | 07/17/2008 |
| 20080145337 | Method and pharmaceutical composition for treating inflammation A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises locally or systemically administering to the subject IFN-gamma in an amount so as to achieve an IFN-gamma bulk tissue concentration at a site of inflammation of 1-8,000 ... | 06/19/2008 |
| 20080131397 | Beta-2-glycoprotein 1 is an inhibitor of angiogenesis The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked β-Glycoprotein 1 (β2GP1) to cells associated with the tissue. The presence of β2GP1 inhibits angiogenesis within the tissue, in part b... | 06/05/2008 |
| 20080124366 | Methods and Compositions for Treating Tumors The present invention is based on the finding that toll-like receptor (TLR) agonists affect immune responses in a subject. The compositions and methods of the present invention include administering to the subject a therapeutically effective amount of a tumor lysate or ... | 05/29/2008 |
| 20080102056 | Marketing System for Improving Patient Compliance and Methods and Devices Relating to Same The present invention provides a marketing system and methods for marketing a dosage form comprising interferon gamma (IFN-γ) to a patient in need thereof, for the treatment of idiopathic pulmonary fibrosis (IPF). The present invention further provides a method for inc... | 05/01/2008 |
| 20080089860 | Therapeutic compositions and methods useful in treating cancer The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment conta... | 04/17/2008 |
| 20080075695 | COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of 5-cyclopropyl-2-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran-3-carboxylic acid methylamide or a pharmaceutically... | 03/27/2008 |
| 20080050340 | CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which con... | 02/28/2008 |
| 20080044377 | Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine In one embodiment, there is provided a method for treatment or prophylaxis of one or more symptoms of a retrovirus infection such as HIV infection, comprising the administration of poxvirus vector encoding a retrovirus antigen and a cytokine, or a functional homolog, de... | 02/21/2008 |
| 20080025944 | Combination Therapy for Immunostimulation The present invention relates to a method for immunostimulation in a mammal, which comprises a. administration of at least one mRNA containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. administration of at least o... | 01/31/2008 |
| 20080019942 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical comp... | 01/24/2008 |
| 20080014173 | Hepatitis C Virus Inhibitors Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.... | 01/17/2008 |
| 20070298009 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in tre... | 12/27/2007 |
| 20070269406 | Transcatheter tumor immunoembolization Methods of inducing a cancer-specific immune response are disclosed through administration of an immune stimulant in the context of tumor cell death induction. Currently used clinical methods of inducing localized tumor cell death are modified to optimize immune respons... | 11/22/2007 |
| 20070264229 | Peptides for Treatment of Autoimmune Disease Peptides are provided that both inhibit more strongly than synthetic amino acid polymers the binding of MBP85-99 to HLA-DR2 (DRA/DRB1*1501), and inhibit interleukin-2 production by two MBP85-99-specific HLA-DR2-restricted T cells. Peptide 15mers J5, J3, and J2 suppress ... | 11/15/2007 |
| 20070258946 | Combination Therapy for Treating Hepatitis C Virus Infection The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reduc... | 11/08/2007 |
| 20070248569 | Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in t... | 10/25/2007 |
| 20070212306 | INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results wherein the composition is free of a stabilizer that is a protein or a polypeptide. In certain aspects of the invention, the inte... | 09/13/2007 |
| 20070196346 | Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer A genetic vaccine construct comprising a poxvirus vector which incorporates and, on administration to a subject, expresses in a cell of said subject a sequence of nucleotides encoding a prostate-specific polypeptide, wherein said poxvirus vector does not productively in... | 08/23/2007 |
